Benefits and risks of long-term low-dose oral continuous combined hormone therapy

Maturitas

Volumn 56, Issue 3, 2007, Pages 231-248

  van de Weijer, P H M ^a   Mattsson, Lars Åke ^b   Ylikorkala, Olavi ^c  

^a GELRE HOSPITALS   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Continuous combined oestrogen progestagen combinations; Hormone therapy; Long term administration started in early postmenopausal women; Long term effect on bone; Long term endometrial safety; Low dose; Pharmacokinetics of estrogens; Pharmacokinetics of progestagens

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DESOGESTREL; DIETHYLSTILBESTROL; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL PLUS TRIMEGESTONE; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL; NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; PLACEBO; TRIMEGESTONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AMENORRHEA; ANXIETY; BIOEQUIVALENCE; BLEEDING; BONE DENSITY; BREAKTHROUGH BLEEDING; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM HYPERPLASIA; FRACTURE; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; UTERUS BLEEDING; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE; RISK FACTORS;

EID: 33846894932     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.08.004     Document Type: Review

References (68)

1. Mattsson L.-A., and Sporrong T. Low dose hormone replacement therapy: clinical efficacy. Minerva Ginecol 55 (2003) 201-207
2. Gambacciani M., and Genazzani A.R. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 40 (2001) 195-201
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
4. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
5. Rees M., and Purdie D.W. Management of the menopause: the handbook of the British Menopause Society. 3rd ed. (2002), BMS Publications Ltd., London
6. Oldenhave A., and Netelenbos C. Pathogenesis of climacteric complaints: ready for the change?. Lancet 343 (1994) 649-653
7. Rödström K., Bengtsson C., Lissner L., Milsom I., Sundh V., and Bjorkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 9 (2002) 156-161
8. Peeyananjarassri K., and Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 8 (2005) 13-23
9. Doren M., and Schneider H.P. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 41 (1996) 29-39
10. Mashchak C.A., Lobo R.A., Dozono-Takano R., et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144 (1982) 511-518
11. Bhavnani B.R., Nisker J.A., Martin J., Aletebi F., Watson L., and Milne J.K. Comparison of pharmacokinetics of a conjugated equine estrogen preparation (Premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. J Soc Gynecol Investig 7 (2000) 175-183
12. Timmer C.J., and Geurts T.B. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study. Eur J Drug Metab Pharmacokinet 24 (1999) 47-53
13. Saavedra I., Leon J., Prado J., Sanchez M.P., Lopez F., and Gaete L. A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. Ther Drug Monit 26 (2004) 482-485
14. Schindler A.F., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46 (2003) S7-S16
15. Sitruk-Ware R. Progestins in the menopause. J Steroid Biochem Mol Biol 69 (1999) 185-193
16. Graziottin A. Libido: the biologic scenario. Maturitas 34 Suppl. 1 (2000) S9-S16
17. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 47 (2004) 277-283
18. Lobo R.A. Absorption and metabolic effects of different types of estrogens and progestogens. Menopause 14 (1987) 143-167
19. Greendale G.A., Reboussin B.A., Hogan P., et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 92 (1998) 982-988
20. Hovik P., Sundsbak H.P., Gaasemyr M., and Sabdvik L. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. Maturitas 11 (1989) 75-82
21. Utian W.H., Shoupe D., Bachmann G., Pinkerton J.V., and Pickar J.H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75 (2001) 1065-1079
22. MacLennan A.H., MacLennan A., Wenzel S., et al. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 159 (1993) 102-106
23. Loh F.H., Chen L.H., Yu S.L., and Jorgensen L.N. The efficacy of two dosages of a hormone replacement continuous combined regimen. Maturitas 41 (2002) 123-131
24. Bærug U., Winge T., Nordland G., et al. Do combinations of 1 mg oestradiol and low doses of NETA effectively control menopausal symptoms?. Climacteric 1 (1998) 219-228
25. Product Monograph. Femoston/Femoston conti. Solvay Pharmaceuticals this all there is.
26. Schurmann R., Holler T., and Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 7 (2004) 189-196
27. Speroff L., Symons J., Kempfert N., and Rowan J. The effect of varying low dose combinations of norethindrone acetate and ethinyl estradiol (Fem HRT) on the frequency and intensity of vasomotor symptoms. Menopause 7 (2000) 383-390
28. Gambacciani M., Ciaponi M., Cappagli B., and Genazzani A.R. Effects of low dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density and metabolism in postmenopausal women. Am J Obstet Gynecol 185 (2001) 1180-1185
29. Heikkinen J.E., Vaheri R.T., Ahomäki S.M., Kainulainen P.M.T., Viitanen A.T., and Timonen U.M. Optimizing continuous combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am J Obstet Gynecol 182 (2000) 560-567
30. Mattsson L.-A., Skouby S.O., Heikkinen J., Vaheri R., Mäenpää J., and Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional dose regimen. Climacteric 7 (2004) 59-69
31. Wehren L.E., and Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep 1 (2003) 78-85
32. Keen R.W. Burden of osteoporosis and fractures. Curr Osteoporos Rep 1 (2003) 66-70
33. Bush T.L., Wells H.B., James M.K., et al. Effects of hormone therapy on bone mineral density-results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276 (1996) 1389-1396
34. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
35. Lindsay R., Gallagher J.C., Kleerekoper M., and Pickar J.H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287 (2002) 2668-2676
36. Lindsay R., Gallagher J.C., Kleerekoper M., and Pickar J.H. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 16 (2005) 372-379
37. Mizunuma H., Okano H., Soda M., et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 27 (1997) 69-76
38. Recker R.R., Davies K.M., Dowd R.M., and Heaney R.P. Low-dose HRT increases bone density in elderly women. Ann Intern Med 130 (1999) 897-904
39. Gambacciani M., Ciaponi M., Cappagli B., et al. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. Maturitas 45 (2003) 175-183
40. Heikkinen J., Vaheri R., Kainulainen P., and Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int 11 (2000) 929-937
41. Heikkinen J, Haapalahti J. Effect of different dose options of continuous combined hormone therapy on bone and bone marker PINP-results from a long-term study in Finnish postmenopausal women. In: Genazzani AR, ed. Postmenopausal osteoporosis: hormones and other therapies, in press.
42. Delmas P.D., Confavreux E., Garnero P., et al. A combination of low doses of 17beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 11 (2000) 177-187
43. Greenwald M.W., Gluck O.S., Lang E., and Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 12 (2005) 741-748
44. Warming L., Ravn P., Spielman D., Delmas P., and Christiansen C. Trimegestone in a low dose continuous combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 11 (2004) 337-342
45. Warming L., Ravn P., Nielsen T., and Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 7 (2004) 103-111
46. Speroff L., Rowan J., Symons J., Genant H., and Wilborn W. The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 276 (1996) 1397-1403
47. Banks E., Beral V., Reeves G., Balkwill A., Barnes I., and for the Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. J Am Med Assoc 291 (2004) 2212-2220
48. Al-Azzawi F., Thompson J., and Stevenson J. Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence. Maturitas 54 (2006) 154-163
49. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
50. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
51. Bruhat M., Rudolf K., Vaheri R., Kainulainen P., Timonen U., and Viitanen A. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy. A randomized comparative dose-ranging study. Maturitas 40 (2001) 259-271
52. Samsioe G., Li C., Borgfeldt C., Wilawan K., Aberg A., and Larsen S. Changes in lipid and lipoprotein profile in postmenopausal women receiving low dose combinations of 17beta-estradiol and norethisterone acetate. Menopause 9 (2002) 335-342
53. Davis S.R., Goldstat R., Newman A., et al. Differing effects of low dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Climacteric 5 (2002) 341-350
54. Borgfeldt C., Li C., and Samsioe G. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric 7 (2004) 78-85
55. Li C., Samsioe G., Borgfeldt C., Bendahl P.O., Kittisak W., and Aberg A. Low dose hormone therapy and carbohydrate metabolism. Fertil Steril 79 (2003) 550-555
56. McKenzie J., Jaap A.J., Gallacher S., et al. Metabolic, inflammatory and haemostatic effects of a low dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?. Clin Endocrinol 59 (2003) 682-689
57. Lobo R.A., Bush T., Carr B.R., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76 (2001) 13-24
58. Heikkinen J., Vaheri R., and Timonen U. Long-term safety and tolerability of continuous combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Men Soc 10 (2004) 95-102
59. Mueck A.O., Rakov V., Keller H., and Hilgers R.D. Bleeding pattern, efficacy and acceptance of low dose continuous combined HRT with estradiol/norethisterone acetate switching directly from oral contraception. Geburtshilfe Frauenheilkunde 65 (2005) 389-395
60. Pickar J.H., Yeh I., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76 (2001) 25-31
61. Pickar J.H., Yeh I.T., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 80 (2003) 1234-1240
62. Beral V., Bull D., and Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
63. Simon J.A., Liu J.H., Speroff L., Shumel B.S., and Symons J.P. Reduced uterine bleeding in postmenopausal women who receive combined norethindrone acetate and low dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 188 (2003) 92-99
64. Jick H., Derby L.E., Myers M.W., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
65. Doren M., and Schneider H.P. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 41 (1996) 29-39
66. Sintonen H., Johansson S., Ohinmaa A., Apajasalo M., Kainulainen P., and Heikkinen J. Measuring health-related quality of life in women on hormone replacement therapy. Expert Rev Pharmacoecon Outcomes Res 3 (2003) 351-361
67. Gambacciani M., Ciaponi M., Cappagli B., et al. Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 44 (2003) 157-163
68. Ylikangas S., Sintonen H., and Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Men Soc 11 (2005) 145-151